These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23065983)

  • 1. Which long-acting bronchodilator is most cost-effective for the treatment of COPD?
    Hoogendoorn M; Kappelhoff BS; Overbeek JA; Wouters EF; Rutten-van Mölken MP
    Neth J Med; 2012 Oct; 70(8):357-64. PubMed ID: 23065983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial.
    Hoogendoorn M; Al MJ; Beeh KM; Bowles D; Graf von der Schulenburg JM; Lungershausen J; Monz BU; Schmidt H; Vogelmeier C; Rutten-van Mölken MP
    Eur Respir J; 2013 Mar; 41(3):556-64. PubMed ID: 22700844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.
    Oostenbrink JB; Rutten-van Mölken MP; Monz BU; FitzGerald JM
    Value Health; 2005; 8(1):32-46. PubMed ID: 15841892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.
    Rutten-van Mölken MP; Oostenbrink JB; Miravitlles M; Monz BU
    Eur J Health Econ; 2007 Jun; 8(2):123-35. PubMed ID: 17370096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of tiotropium and salmeterol in the treatment of chronic obstructive pulmonary disease (COPD) in Greece.
    Maniadakis N; Tzanakis N; Fragoulakis V; Hatzikou M; Siafakas N
    Curr Med Res Opin; 2006 Aug; 22(8):1599-607. PubMed ID: 16870084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.
    Sun SX; Marynchenko M; Banerjee R; Cheng D; Mocarski M; Yin D; Yu AP; Wu EQ
    J Med Econ; 2011; 14(6):805-15. PubMed ID: 21992217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of long-acting bronchodilators for chronic obstructive pulmonary disease.
    Oba Y
    Mayo Clin Proc; 2007 May; 82(5):575-82. PubMed ID: 17493425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-utility analysis of indacaterol in Germany: a once-daily maintenance bronchodilator for patients with COPD.
    Price D; Gray A; Gale R; Asukai Y; Mungapen L; Lloyd A; Peters L; Neidhardt K; Gantner T
    Respir Med; 2011 Nov; 105(11):1635-47. PubMed ID: 21764277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of tiotropium versus usual care in patients with COPD in the UK and Belgium.
    Hettle R; Wouters H; Ayres J; Gani R; Kelly S; Lion M; Decramer M
    Respir Med; 2012 Dec; 106(12):1722-33. PubMed ID: 23040833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of salmeterol, fluticasone, and combination therapy for COPD.
    Oba Y
    Am J Manag Care; 2009 Apr; 15(4):226-32. PubMed ID: 19355795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients.
    Vogelmeier C; Fabbri LM; Rabe KF; Beeh KM; Schmidt H; Metzdorf N; Glaab T
    Respir Med; 2013 Jan; 107(1):75-83. PubMed ID: 23102611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.
    Najafzadeh M; Marra CA; Sadatsafavi M; Aaron SD; Sullivan SD; Vandemheen KL; Jones PW; Fitzgerald JM
    Thorax; 2008 Nov; 63(11):962-7. PubMed ID: 18621985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A UK-based cost-utility analysis of indacaterol, a once-daily maintenance bronchodilator for patients with COPD, using real world evidence on resource use.
    Price D; Asukai Y; Ananthapavan J; Malcolm B; Radwan A; Keyzor I
    Appl Health Econ Health Policy; 2013 Jun; 11(3):259-74. PubMed ID: 23529714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium versus salmeterol for the prevention of exacerbations of COPD.
    Vogelmeier C; Hederer B; Glaab T; Schmidt H; Rutten-van Mölken MP; Beeh KM; Rabe KF; Fabbri LM;
    N Engl J Med; 2011 Mar; 364(12):1093-1103. PubMed ID: 21428765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Economic value of tiotropium in the treatment of chronic obstructive pulmonary disease].
    Schramm W; Haake D; Brandt A
    Praxis (Bern 1994); 2005 Nov; 94(46):1803-10. PubMed ID: 16329401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analyses comparing tiotropium with ipratropium or salmeterol in UK patients with COPD.
    Gani R; Griffin J; Kelly S; Rutten-van Mölken M
    Prim Care Respir J; 2010 Mar; 19(1):68-74. PubMed ID: 20094687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cost-effectiveness analysis of tiotropium compared to ipratropium and salmeterol].
    García Ruiz AJ; Leiva Fernández F; Martos Crespo F
    Arch Bronconeumol; 2005 May; 41(5):242-8. PubMed ID: 15919004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
    Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
    Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of fluticasone propionate/salmeterol (500/50 microg) in the treatment of COPD.
    Earnshaw SR; Wilson MR; Dalal AA; Chambers MG; Jhingran P; Stanford R; Mapel DW
    Respir Med; 2009 Jan; 103(1):12-21. PubMed ID: 19010652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.